Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Toru Takenaka
TAS4464, a Highly Potent and Selective Inhibitor of NEDD8 Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Stereoselective Metabolism of Racemic Carvedilol by UGT1A1 and UGT2B7, and Effects of Mutation of These Enzymes on Glucuronidation Activity
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Related publications
TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Activity of TAS4464, a Novel NEDD8 Activating Enzyme E1 Inhibitor, Against Multiple Myeloma via Inactivation of NF‐κB Pathways
Cancer Science
Cancer Research
Medicine
Oncology
Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models
International Journal of Cancer
Cancer Research
Oncology
CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase With Antitumor Activity in Experimental Models of Human Cancers
Molecular Cancer Therapeutics
Cancer Research
Oncology
The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth
Cancer Research
Cancer Research
Oncology
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors
Clinical Cancer Research
Cancer Research
Oncology
Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924
Cancer Cell
Cancer Research
Oncology
Cell Biology
Selective Inhibition of BCL2 Shows Antitumor Effects in Lung Cancer
Cancer Discovery
Oncology
Pevonedistat, a Nedd8-Activating Enzyme Inhibitor, Sensitizes Neoplastic B-Cells to Death Receptor-Mediated Apoptosis
Oncotarget
Oncology
